EMERGE trial

The EMERGE trial was a research study that tested the effectiveness of a medicine called lecanemab for treating early-stage Alzheimer’s disease. It involved participants with mild cognitive impairment or early dementia symptoms. The goal was to see if lecanemab could slow brain decline by reducing the buildup of harmful proteins called amyloid plaques. The trial found that those taking lecanemab experienced a slower decline in thinking and memory abilities compared to those on a placebo. This study provides evidence that targeting amyloid plaques may be a promising approach to modifying the disease’s progression.